Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luciano Mutti

Showing results (21-30 of 124) with videos related to

Pageof 13
Sort By:
BMC Cancer|February 24, 2010
In vitro and in vivo characterization of highly purified human mesothelioma derived cellsAlice Melotti, Antonio Daga, Daniela Marubbi, et al.
Expert Review of Anticancer Therapy|July 21, 2017
Immunotherapy advances for mesothelioma treatmentEmyr Bakker, Alice Guazzelli, Firozeh Ashtiani, et al.
Nature Clinical Practice. Oncology|January 30, 2008
Advances in the systemic therapy of malignant pleural mesotheliomaDean A Fennell, Giovanni Gaudino, Kenneth J O'Byrne, et al.
Oncotarget|February 10, 2016
Targeting hypoxic response for cancer therapyElisa Paolicchi, Federica Gemignani, Marija Krstic-Demonacos, et al.
Lung Cancer (Amsterdam, Netherlands)|October 26, 2002
Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?Camillo Porta, Vittoria Rizzo, Matteo Zimatore, et al.
Expert Opinion on Investigational Drugs|July 7, 2017
Promising investigational drug candidates in phase I and phase II clinical trials for mesotheliomaAlice Guazzelli, Emyr Bakker, Kun Tian, et al.
Immunotherapy|February 25, 2017
Anti-CTLA-4 therapy for malignant mesotheliomaAlice Guazzelli, Emyr Bakker, Marija Krstic-Demonacos, et al.
International Journal of Molecular Sciences|April 3, 2021
Identification of Overexpressed Genes in Malignant Pleural MesotheliomaFederica Morani, Luisa Bisceglia, Giulia Rosini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenograftsPietro Bertino, Federica Piccardi, Camillo Porta, et al.
Journal of Cellular and Molecular Medicine|January 11, 2013
PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1Giulia Pinton, Arcangela Gabriella Manente, Bruno Murer, et al.
Pageof 13

Showing results (21-30 of 124) with videos related to

Sort By:
Pageof 13
BMC Cancer|February 24, 2010
In vitro and in vivo characterization of highly purified human mesothelioma derived cellsAlice Melotti, Antonio Daga, Daniela Marubbi, et al.
Expert Review of Anticancer Therapy|July 21, 2017
Immunotherapy advances for mesothelioma treatmentEmyr Bakker, Alice Guazzelli, Firozeh Ashtiani, et al.
Nature Clinical Practice. Oncology|January 30, 2008
Advances in the systemic therapy of malignant pleural mesotheliomaDean A Fennell, Giovanni Gaudino, Kenneth J O'Byrne, et al.
Oncotarget|February 10, 2016
Targeting hypoxic response for cancer therapyElisa Paolicchi, Federica Gemignani, Marija Krstic-Demonacos, et al.
Lung Cancer (Amsterdam, Netherlands)|October 26, 2002
Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?Camillo Porta, Vittoria Rizzo, Matteo Zimatore, et al.
Expert Opinion on Investigational Drugs|July 7, 2017
Promising investigational drug candidates in phase I and phase II clinical trials for mesotheliomaAlice Guazzelli, Emyr Bakker, Kun Tian, et al.
Immunotherapy|February 25, 2017
Anti-CTLA-4 therapy for malignant mesotheliomaAlice Guazzelli, Emyr Bakker, Marija Krstic-Demonacos, et al.
International Journal of Molecular Sciences|April 3, 2021
Identification of Overexpressed Genes in Malignant Pleural MesotheliomaFederica Morani, Luisa Bisceglia, Giulia Rosini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenograftsPietro Bertino, Federica Piccardi, Camillo Porta, et al.
Journal of Cellular and Molecular Medicine|January 11, 2013
PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1Giulia Pinton, Arcangela Gabriella Manente, Bruno Murer, et al.
Pageof 13